These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 12663723)
1. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723 [TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547 [TBL] [Abstract][Full Text] [Related]
3. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828 [TBL] [Abstract][Full Text] [Related]
4. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880 [TBL] [Abstract][Full Text] [Related]
5. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219 [TBL] [Abstract][Full Text] [Related]
6. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948 [TBL] [Abstract][Full Text] [Related]
7. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Dervieux T; Hancock M; Evans W; Pui CH; Relling MV Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287 [TBL] [Abstract][Full Text] [Related]
8. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952 [TBL] [Abstract][Full Text] [Related]
9. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Schmiegelow K; Heyman M; Gustafsson G; Lausen B; Wesenberg F; Kristinsson J; Vettenranta K; Schroeder H; Forestier E; Rosthoej S; Leukemia; 2010 Apr; 24(4):715-20. PubMed ID: 20130603 [TBL] [Abstract][Full Text] [Related]
10. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U; J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786 [TBL] [Abstract][Full Text] [Related]
11. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia. Schmiegelow K; Ifversen M Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815 [TBL] [Abstract][Full Text] [Related]
12. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia. Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report. Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455 [TBL] [Abstract][Full Text] [Related]
14. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299 [TBL] [Abstract][Full Text] [Related]
15. Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters? Schmiegelow K; Schrøder H; Schmiegelow M Cancer Chemother Pharmacol; 1994; 34(3):209-15. PubMed ID: 8004753 [TBL] [Abstract][Full Text] [Related]
16. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411 [TBL] [Abstract][Full Text] [Related]
17. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426 [TBL] [Abstract][Full Text] [Related]
18. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Nygaard U; Toft N; Schmiegelow K Clin Pharmacol Ther; 2004 Apr; 75(4):274-81. PubMed ID: 15060506 [TBL] [Abstract][Full Text] [Related]
19. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F; Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654 [TBL] [Abstract][Full Text] [Related]